News
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
After three years of availability via the Cancer Drugs Fund (CDF), MSD's checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to pr
